Bamias Giorgos, Mishina Margarita, Nyce Mark, Ross William G, Kollias Giorgos, Rivera-Nieves Jesus, Pizarro Theresa T, Cominelli Fabio
Digestive Health Center of Excellence, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA.
Proc Natl Acad Sci U S A. 2006 May 30;103(22):8441-6. doi: 10.1073/pnas.0510903103. Epub 2006 May 12.
TL1A is a TNF-like cytokine that binds to the death-domain receptor (DR)3 and provides costimulatory signals to activated lymphocytes. Through this interaction, TL1A induces secretion of IFN-gamma and may, therefore, participate in the development of T helper-1-type effector responses. In this study, we investigated whether interactions between TL1A and DR3 are involved in the pathogenesis of chronic murine ileitis. We demonstrate that alternative splicing of DR3 mRNA takes place during the activation of lymphocytes, which results in up-regulation of the complete/transmembrane (tm) form of DR3. Using two immunogenetically distinct animal models of Crohn's disease, we demonstrate that induction of intestinal inflammation is associated with significant up-regulation of TL1A and tm DR3 in the inflamed mucosa. In addition, within isolated lamina propria mononuclear cells from mice with inflammation, TL1A is primarily expressed on CD11c(high) dendritic cells. We also report that TL1A acts preferentially on memory CD4(+)/CD45RB(lo) murine lymphocytes by significantly inducing their proliferation, whereas it does not affect the proliferation of the naïve CD4(+)/CD45RB(hi) T helper cell subpopulation. Finally, we demonstrate that TL1A synergizes with both the cytokine-dependent IL-12/IL-18 pathway and with low-dose stimulation of the T cell receptor to significantly induce the secretion of IFN-gamma via an IL-18-independent pathway. Our results raise the possibility that interaction(s) between TL1A expressed on antigen-presenting cells and tm DR3 on lymphocytes may be of particular importance for the pathogenesis of chronic inflammatory conditions that depend on IFN-gamma secretion, including inflammatory bowel disease. Blockade of the TL1A/DR3 pathway may, therefore, offer therapeutic opportunities in Crohn's disease.
TL1A是一种肿瘤坏死因子样细胞因子,它与死亡结构域受体(DR)3结合,并为活化的淋巴细胞提供共刺激信号。通过这种相互作用,TL1A诱导γ干扰素的分泌,因此可能参与辅助性T细胞1型效应反应的发展。在本研究中,我们调查了TL1A与DR3之间的相互作用是否参与慢性小鼠回肠炎的发病机制。我们证明,DR3 mRNA的可变剪接发生在淋巴细胞活化过程中,这导致DR3的完整/跨膜(tm)形式上调。使用两种免疫遗传学上不同的克罗恩病动物模型,我们证明肠道炎症的诱导与炎症黏膜中TL1A和tm DR3的显著上调有关。此外,在来自炎症小鼠的分离的固有层单核细胞中,TL1A主要表达于CD11c(高)树突状细胞上。我们还报告说,TL1A通过显著诱导其增殖而优先作用于记忆性CD4(+)/CD45RB(低)小鼠淋巴细胞,而它不影响幼稚CD4(+)/CD45RB(高)辅助性T细胞亚群的增殖。最后,我们证明TL1A与细胞因子依赖性白细胞介素12/白细胞介素18途径以及与低剂量的T细胞受体刺激协同作用,通过白细胞介素18非依赖性途径显著诱导γ干扰素的分泌。我们的结果提出了一种可能性,即抗原呈递细胞上表达的TL1A与淋巴细胞上的tm DR3之间的相互作用对于依赖γ干扰素分泌的慢性炎症性疾病(包括炎症性肠病)的发病机制可能特别重要。因此,阻断TL1A/DR3途径可能为克罗恩病提供治疗机会。